|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Current assets: | ||||||||||||
| Cash | ||||||||||||
| Prepaid expenses | ||||||||||||
| Total current assets | ||||||||||||
| Cash held in Trust Account | ||||||||||||
| Total Assets | ||||||||||||
| Liabilities, Class A Ordinary Shares Subject to Redemption and Shareholders' Deficit | ||||||||||||
| Current liabilities: | ||||||||||||
| Accounts payable | ||||||||||||
| Accrued expenses | ||||||||||||
| Due to related party | ||||||||||||
| Promissory note-related party | ||||||||||||
| Total current liabilities | ||||||||||||
| Derivative warrant liabilities | ||||||||||||
| Deferred underwriting commissions | ||||||||||||
| Total Liabilities | ||||||||||||
| Class A ordinary shares subject to possible redemption, $0.0001 par value; 4,639,867 and 6,794,168 shares issued and outstanding at approximately $10.64 and $10.26 per share redemption value as of June 30, 2023 and December 31, 2022, respectively | ||||||||||||
| Shareholders' Deficit | ||||||||||||
| Common stock | ||||||||||||
| Common Class A | ||||||||||||
| Common Class B | ||||||||||||
| Additional paid-in capital | ||||||||||||
| Accumulated deficit | ||||||||||||
| Total Shareholders' Deficit | ||||||||||||
| Total Liabilities, Class A Ordinary Shares Subject to Redemption and Shareholders' Deficit |
Loading...
